We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$512M
AUM Growth
-$81.4M
Cap. Flow
-$45M
Cap. Flow %
-8.79%
Top 10 Hldgs %
73.66%
Holding
32
New
4
Increased
5
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$45M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$16.6M
3
COGT icon
Cogent Biosciences
COGT
+$10.8M
4
PLRX icon
Pliant Therapeutics
PLRX
+$9.96M
5
FULC icon
Fulcrum Therapeutics
FULC
+$7.7M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$51.7M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$44.7M
3
NVAX icon
Novavax
NVAX
+$19.3M
4
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$11.8M
5
LIAN
LianBio American Depositary Shares
LIAN
+$7.86M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$11.2B
– –
-670,718
Closed -$51.7M
INZY
27
DELISTED
Inozyme Pharma
INZY
– –
-2,709,987
Closed -$2.85M
NVAX icon
28
Novavax
NVAX
$1.2B
– –
-1,879,894
Closed -$19.3M
ATYR
29
aTyr Pharma
ATYR
$47.6M
– –
-1,171,436
Closed -$2.57M
MRNS
30
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-1,770,705
Closed -$7.05M
LIAN
31
DELISTED
LianBio American Depositary Shares
LIAN
– –
-4,793,047
Closed -$7.86M
PRVB
32
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-1,118,653
Closed -$11.8M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2023 Portfolio in Review

As of Q1 2023, VR Adviser held 32 positions worth $512M, down 14% from $594M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

VR Adviser withdrew a net $45M in Q1 2023, closing 7 positions and reducing 2 holdings. Its most notable exit was Axsome Therapeutics, an estimated $51.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, VR Adviser opened a new position in Enliven Therapeutics worth $48.5M.

  • VR Adviser's largest Q1 2023 buy was Enliven Therapeutics: 2,214,142 shares worth $48.5M.
  • VR Adviser added most to Cogent Biosciences in Q1 2023, an estimated $10.8M increase.
  • VR Adviser's biggest Q1 2023 reduction was Aclaris Therapeutics, cutting an estimated $44.7M.
  • VR Adviser fully exited Axsome Therapeutics in Q1 2023, selling an estimated $51.7M.
  • VR Adviser's ten largest holdings make up 74% of its $512M portfolio in Q1 2023.
  • VR Adviser opened 4 new positions and closed 7 in Q1 2023.
  • VR Adviser's portfolio value fell 14% quarter-over-quarter to $512M.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.